Risk assessment of "other substances" – L-proline. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety.
dc.contributor.author | Holvik, Kristin | |
dc.contributor.author | Frøyland, Livar | |
dc.contributor.author | Haugen, Margaretha | |
dc.contributor.author | Henjum, Sigrun | |
dc.contributor.author | Løvik, Martinus | |
dc.contributor.author | Skålhegg, Bjørn Steen | |
dc.contributor.author | Stea, Tonje Holte | |
dc.contributor.author | Strand, Tor A | |
dc.contributor.author | Tell, Grethe S. | |
dc.contributor.author | Iversen, Per Ole | |
dc.date.accessioned | 2017-10-18T10:52:29Z | |
dc.date.available | 2017-10-18T10:52:29Z | |
dc.date.created | 2017-10-17T14:06:08Z | |
dc.date.issued | 2016 | |
dc.identifier.isbn | 978-82-8259-250-5 | |
dc.identifier.uri | http://hdl.handle.net/11250/2460754 | |
dc.description.abstract | At the request of the Norwegian Food Safety Authority, the Norwegian Scientific Committee for Food Safety (VKM) has characterised the risk of specified doses of L-proline in food supplements. VKM concludes that: • In adults (≥18 years), the specified doses 50, 500, 1000, 1500 and 1800 mg/day Lproline in food supplements are unlikely to cause adverse health effects. • In adolescents (14 to < 18 years), the specified doses 50, 500, 1000, 1500 and 1800 mg/day L-proline in food supplements are unlikely to cause adverse health effects. • In children (10 to < 14 years), the specified doses 50, 500, 1000, 1500 and 1800 mg/day L-proline in food supplements are unlikely to cause adverse health effects. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Norwegian Scientific Committee for Food Safety (VKM) | nb_NO |
dc.relation.ispartof | VKM Report | |
dc.relation.ispartofseries | VKM Report; | |
dc.title | Risk assessment of "other substances" – L-proline. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety. | nb_NO |
dc.type | Research report | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 38 | nb_NO |
dc.source.issue | 2016:61 | nb_NO |
dc.identifier.cristin | 1505201 | |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original |